RGNX is focused on developing, commercializing and licensing recombinant adeno-associated virus gene therapy with a proprietary delivery platform to treat rare diseases. RGNX is commercializing gene therapy products administered directly into the body, or in vivo, based on a NAV Technology Platform. Its NAV Technology Platform is currently being applied in the development of 23 product candidates for a variety of diseases, Regenxbio said, with exclusive rights to over 100 patents and patent applications worldwide.
April 20, 2017
RegMed Investors’ (RMi) closing bell analysis: markets revved-up to record close
April 20, 2017
RegMed Investors’ (RMi) pre-open indications, the love/hate relationship with sector risks …
April 19, 2017
RegMed Investors’ (RMi) closing bell analysis: the sector pricing accelerated
April 19, 2017
RegMed Investors’ (RMi) pre-open indications, higher open expected
April 18, 2017
RegMed Investors’ (RMi) closing bell analysis: the cell therapy sector needs to rethink its perception
April 18, 2017
RegMed Investors’ (RMi) pre-open indications lower open expected
April 17, 2017
RegMed Investors’ (RMi) closing bell analysis: market climbs as sector tweaks
April 17, 2017
RegMed Investors’ (RMi) pre-open indications lower open expected
March 30, 2017
RegMed Investors’ (RMi) closing bell analysis: the sector’s Icarus effect
March 29, 2017
RegMed Investors’ (RMi) closing bell analysis: is the sector blowing name bubbles?
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.